Genscript Biotech Revenue vs. Cash Per Share
| GNNSF Stock | USD 1.25 0.01 0.79% |
For Genscript Biotech profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Genscript Biotech to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Genscript Biotech utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Genscript Biotech's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Genscript Biotech over time as well as its relative position and ranking within its peers.
Genscript |
Genscript Biotech Cash Per Share vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Genscript Biotech's current stock value. Our valuation model uses many indicators to compare Genscript Biotech value to that of its competitors to determine the firm's financial worth. Genscript Biotech is rated as one of the top companies in revenue category among its peers. It also is one of the top stocks in cash per share category among its peers . The ratio of Revenue to Cash Per Share for Genscript Biotech is about 851,001,667 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Genscript Biotech's earnings, one of the primary drivers of an investment's value.Genscript Revenue vs. Competition
Genscript Biotech is rated as one of the top companies in revenue category among its peers. Market size based on revenue of Biotechnology industry is currently estimated at about 27.37 Billion. Genscript Biotech claims roughly 510.6 Million in revenue contributing just under 2% to stocks in Biotechnology industry.
Genscript Cash Per Share vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Genscript Biotech |
| = | 510.6 M |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Genscript Biotech |
| = | 0.60 X |
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
Genscript Cash Per Share Comparison
Genscript Biotech is currently under evaluation in cash per share category among its peers.
Genscript Biotech Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Genscript Biotech, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Genscript Biotech will eventually generate negative long term returns. The profitability progress is the general direction of Genscript Biotech's change in net profit over the period of time. It can combine multiple indicators of Genscript Biotech, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in North America, Europe, the Peoples Republic of China, Japan, the other Asia Pacific regions, and internationally. Genscript Biotech Corporation was founded in 2002 and is headquartered in Nanjing, the Peoples Republic of China. Genscript Biotech operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 5573 people.
Genscript Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Genscript Biotech. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Genscript Biotech position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Genscript Biotech's important profitability drivers and their relationship over time.
Use Genscript Biotech in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Genscript Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Genscript Biotech will appreciate offsetting losses from the drop in the long position's value.Genscript Biotech Pair Trading
Genscript Biotech Pair Trading Analysis
The ability to find closely correlated positions to Genscript Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Genscript Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Genscript Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Genscript Biotech to buy it.
The correlation of Genscript Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Genscript Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Genscript Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Genscript Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Genscript Biotech position
In addition to having Genscript Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Materials ETFs Thematic Idea Now
Materials ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Materials ETFs theme has 51 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Materials ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Genscript Pink Sheet
To fully project Genscript Biotech's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Genscript Biotech at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Genscript Biotech's income statement, its balance sheet, and the statement of cash flows.